Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Exec. Director, Finance - PAO | December 19, 2022 | December 21, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date December 19, 2022 · Filed December 21, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,653 |
Reported balance
After 2022-12-19 transaction · row 1
1 source rowRow 1 · 2022-12-19 · Grant · Acquired 5,900 · Balance 16,653 F1: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.63 · Expires 2032-12-19 | Direct | 8,500 |
Reported balance
After 2022-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-19 · Grant · Acquired 8,500 · Balance 8,500 F2: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.
F2: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2022 Filed Dec 21, 2022 21:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 8,500 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0001127602-22-028078 · form4.xml · derivative · entry 2 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires 2032-12-19 F2 · derivative.exercise_date: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 19, 2022 Filed Dec 21, 2022 21:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-028078 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,653 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 15, 2022 Filed Dec 19, 2022 21:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 445 | $10.90 | $4,850.50 |
DisclosureSEC source: 0001127602-22-027870 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,753 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2022 to cover tax withholding obligations in connection with the vesting of 1,462 Restricted Stock Units. The sale occurred automatically to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F2 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $10.54 to $11.40. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 23:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 8,600 | $0.00 Strike: $1.42 | $0.00 |
DisclosureSEC source: 0001127602-22-026834 · form4.xml · derivative · entry 3 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,600 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 23:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 8,600 | $13.01 | $111,886.00 |
DisclosureSEC source: 0001127602-22-026834 · form4.xml · nonDerivative · entry 2 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 F1 · price: The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.01 to $13.03. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| December 01, 2022 Filed Dec 2, 2022 23:36 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 8,600 | $1.42 | $12,212.00 |
DisclosureSEC source: 0001127602-22-026834 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,798 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 2,300 | $0.00 Strike: $4.73 | $0.00 |
DisclosureSEC source: 0001127602-22-008047 · form4.xml · derivative · entry 3 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires 2022-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | SaleCommon Stock | 2,300 | $17.20 | $39,560.00 |
DisclosureSEC source: 0001127602-22-008047 · form4.xml · nonDerivative · entry 2 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:04 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 2,300 | $4.73 | $10,879.00 |
DisclosureSEC source: 0001127602-22-008047 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 11,700 | $0.00 Strike: $11.43 | $0.00 |
DisclosureSEC source: 0001127602-21-031141 · form4.xml · derivative · entry 2 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,700 Underlying: Common Stock · 11,700 shares Expires 2031-12-14 F2 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantCommon Stock | 5,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-031141 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,198 F1 · shares: Annual award of Restricted Stock Units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionEmp. Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $3.51 | $0.00 |
DisclosureSEC source: 0001127602-21-011668 · form4.xml · derivative · entry 2 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,500 shares Expires 2021-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 20:19 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | Exercise / conversionCommon Stock | 4,500 | $3.51 | $15,795.00 |
DisclosureSEC source: 0001127602-21-011668 · form4.xml · nonDerivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:41 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031800 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-12-15 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 21:24 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $5.45 | $0.00 |
DisclosureSEC source: 0001127602-20-030706 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2023-08-08 F1 · date: On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 21:49 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-007687 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,800 Underlying: Common Stock · 2,800 shares Expires 2024-12-22 F1 · date: On February 21, 2020, the company received payment for 20,000 doses of RAPIVAB? (peramivir injection) delivered to the U.S. Department of Health and Human Services under the company's procurement contract. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 20% of the performance-based stock options vested. Read SEC document |
| February 14, 2020 Filed Feb 19, 2020 22:13 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 4,900 | $0.00 Strike: $11.13 | $0.00 |
DisclosureSEC source: 0001127602-20-006508 · form4.xml · derivative · entry 1 Jones Michael L · CIK 0001800060 · Exec. Director, Finance - PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,900 Underlying: Common Stock · 4,900 shares Expires 2024-12-22 F1 · date: On February 18, 2019, BioCryst Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted and filed its new drug application for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema attacks. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in December 2014, excluding the Chief Executive Officer, has been met. Therefore, 35% of the performance-based stock options vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.